Join to View Full Profile
250 25th Ave NSte 412Nashville, TN 37203
Phone+1 615-986-7000
Fax+1 615-986-7601
Join Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 4 invites waiting! - Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Jesus Berdeja, MD is an oncologist in Nashville, Tennessee. He is currently licensed to practice medicine in Tennessee, Alabama, and Georgia.
Education & Training
Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1998 - 2001
University of California (San Francisco)Residency, Internal Medicine, 1994 - 1997
Harvard Medical SchoolClass of 1994
Certifications & Licensure
CA State Medical License 1996 - Present
KY State Medical License 2025 - 2027
TN State Medical License 2008 - 2027
GA State Medical License 2025 - 2026
AL State Medical License 2025 - 2025
MD State Medical License 1998 - 2002
American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification ARIA Oncology Information System (for Medical Oncology), Varian Medical Systems, 2012, 2014-2017
- CMS Meaningful Use Stage 1 Certification ARIA oncology information system (for Medical Oncology), Varian Medical Systems, 2012, 2014-2017
Publications & Presentations
PubMed
- 29 citationsInternational myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma.Luciano J Costa, Rahul Banerjee, Hira Mian, Katja Weisel, Susan Bal
Leukemia. 2025-03-01 - 11 citationsAccess barriers to anti-CD19+ CART therapy for NHL across a community transplant and cellular therapy network.Minoo Battiwalla, Michael Tees, Ian Flinn, Jeremy Pantin, Jesus Berdeja
Blood Advances. 2025-01-28 - 44 citationsIde-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses.Sikander Ailawadhi, Bertrand Arnulf, Krina Patel, Michele Cavo, Ajay K Nooka
Blood. 2024-12-05
Press Mentions
Sarah Cannon to Present Latest Cancer Research Insights at 2021 ASCO® Annual MeetingJune 4th, 2021- Subcutaneous Bispecific Antibodies Are Effective in Pre-Treated Multiple MyelomaJune 2nd, 2021
- VRd Still Reigns in Newly Diagnosed MyelomaJune 1st, 2020
